Emergent BioSolutions (EBS) Gross Margin (2011 - 2026)

Emergent BioSolutions' Gross Margin history runs 16 years deep, the most recent figure standing at 53.88% for Q1 2026.

• In Q1 2026, Gross Margin fell 630.0% year-over-year to 53.88%; the TTM figure through Mar 2026 stood at 54.24% (up 408.0% YoY), while the FY2025 annual figure was 56.09%, up 2137.0% from the prior year.
• Gross Margin was 53.88% for Q1 2026 at Emergent BioSolutions, up from 42.91% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 99.7% in Q1 2022 to a low of 6.94% in Q1 2023.
• Historically, Gross Margin has averaged 51.32% across 5 years, with a median of 52.19% in 2024.
• The sharpest annual moves came in 2023 and 2024: Gross Margin slumped 9277 bps in 2023, then jumped 4493 bps in 2024.
• A 5-year view of Gross Margin shows it stood at 49.33% in 2022, then slumped by 33 bps to 33.08% in 2023, then grew by 19 bps to 39.39% in 2024, then increased by 9 bps to 42.91% in 2025, then gained by 26 bps to 53.88% in 2026.
• The last three Gross Margin figures came in at 53.88% (Q1 2026), 42.91% (Q4 2025), and 62.83% (Q3 2025), per Business Quant data.